Cancer diagnosis and therapy solutions provider IBA and international medical technology group Elekta AB have come together to launch a global particle therapy collaboration program. Their goal is to optimize the smooth integration of proton therapy delivery and information management systems within the radiation oncology environment.

Also joining in the initiative is CMS, a St. Louis-based radiation treatment planning developer.

The program’s objective is to offer fully integrated, open and comprehensive cancer treatment solutions to the particle therapy market.

Under the deal, IBA, Elekta and CMS will provide particle therapy solutions packages to meet specific clinical requirements. Products and solutions include Elekta’s MOSAIQ workflow management and information system, MOSAIQ Proton Therapy module and Elekta Synergy® advanced IMRT and IGRT delivery system, in addition to IBA’s comprehensive Proteus system. IBA and Elekta have also agreed to team up in sales and marketing. 

According to the companies, more components and solutions may be added in the future based on customer requirements.